Cluenex
Log inStart free
All stocks · Healthcare · Health Care Supplies

Align Technology ALGN

Align Technology scores good on business quality (6.1 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$142.71Oct 9, 2026
Business qualityGood
Next earningsOct 28, 2026, after the close
Insiders, 90 daysQuiet

Why it matters

  1. What Align Technology does

    Align Technology makes clear aligners and dental scanners, selling directly to orthodontists and general dentists who treat patients requiring malocclusion correction. The business relies on dental professionals adopting its digital treatment planning software alongside custom plastic appliances. Growth has stalled near zero with revenue at $4.1 billion as adoption faces severe macroeconomic friction.

  2. What it does best

    Align dominates clear aligner manufacturing through extensive clinical databases and practitioner relationships, posting a gross margin of 69% compared to MDLN at 26%. This high margin reflects deep practitioner lock-in via its proprietary iTero scanners and treatment software.

  3. The main risk

    Demand contraction among discretionary orthodontic patients threatens volume, leaving revenue growth stagnant at 0.9% and dragging the growth score down to 1.9. Practitioners are deferring major case starts as consumer spending tightens.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityFair

Operating margin sits at 16.8% with a net margin of 10.0%, yielding a modest 10.1% ROE. Profitability faces pressure as top-line stagnation limits scale advantages.

MoatStrong

Doctor network lock-in creates a formidable barrier, backed by a 63rd percentile sector gross margin of 69.0%. Rivals struggle to replicate the proprietary clinical database built over decades.

GrowthSlow

Revenue growth crawled to 0.9% with $4.1B in annual sales, marking a sharp deceleration from historical periods and dragging performance to the bottom decile of its sector.

Financial healthStrong

Debt-free balance sheet with $1.1B in cash and zero debt keeps solvency airtight. Free cash flow reached $634M, providing immense safety.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

No open market buys or unplanned sales by executives or directors.

Our sealed record on ALGN

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is ALGN a good business?

Align Technology scores good on the Cluenex quality check (6.1 of 10), measured against its own industry. Profitability is fair, moat strong, growth slow and financial health strong.

Are insiders buying ALGN?

In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.

When does ALGN report earnings?

Oct 28, 2026, after the close.

For members

See ALGN today

  • Today's verdict on ALGN, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Align Technology (ALGN)”, https://cluenex.com/stocks/algn/, data as of Oct 10, 2026.